Patent Oppositions in peptide drugs industry

Explore the competitive field of peptide drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in peptide drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the peptide drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the peptide drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 1, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Treatment Of Post-Operative Surgical PainIPSEN BIOPHARMSep 17, 2026MERZ PHARMA
Hydrolyzed Collagen For Use In Reducing Blood GlucoseROUSSELOTSep 16, 2026GELITA
Methods Of Treating Crohn'S Disease With Anti-Il23 Specific AntibodyJANSSEN BIOTECHSep 14, 2026SIMMONS & SIMMONS
Composition For Enteral IntakeMORINAGA MILK INDUSTRYSep 9, 2026FRESENIUS KABI DEUTSCHLAND
Process For Producing A Tablet Comprising Glp-1 PeptidesNOVO NORDISKSep 3, 2026ZBM PATENTS
Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIMSep 2, 2026BARDEHLE PAGENBERG
Process For Producing A Tablet Comprising Glp-1 PeptidesNOVO NORDISKSep 2, 2026CMS CAMERON MCKENNA NABARRO OLSWANG
High Concentration Vegf Receptor Fusion Protein Containing FormulationsREGENERON PHARMACEUTICALSAug 26, 2026KARO
High Concentration Vegf Receptor Fusion Protein Containing FormulationsREGENERON PHARMACEUTICALSAug 25, 2026QILU PHARMACEUTICAL
High Concentration Vegf Receptor Fusion Protein Containing FormulationsREGENERON PHARMACEUTICALSAug 24, 2026SANDOZ

To stay ahead in the competitive peptide drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the peptide drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 1, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Nov 26, 2025High Concentration Vegf Receptor Fusion Protein Containing FormulationsREGENERON PHARMACEUTICALS13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11
Sep 3, 2025Extended, High Dose Vegf Antagonist Regimens For Treatment Of Angiogenic Eye DisordersBAYER HEALTHCARE10
Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS9
Apr 24, 2024Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA9
Aug 10, 2022Semaglutide In Cardiovascular ConditionsNOVO NORDISK8
Feb 7, 2024Glp-1 Compositions And Uses ThereofNOVO NORDISK8
Aug 7, 2019Methods To Mobilize Progenitor/Stem CellsGENZYME7